Journal of Turkish Clinical Biochemistry

The official publication of Turkish Society of Clinical Biochemistry

Diamond OA
No APCs
First Decision
30 Days
Indexed In
TR Dizin
Case Report
August 01, 2015
JTCB. 2015 Aug 1; 13 (2) : 069-073

Complete Blood Count in Cold Agglutinin Disease

1 Antalya Eğitim ve Araştırma Hastanesi, Biyokimya, Antalya, Türkiye

Abstract

Background: Cold agglutinin disease is a rare autoimmune hemolytic disease causing the agglutination of erythrocytes by the activation of antibodies at low temperatures. Cold agglutinin disease should be kept in mind in terms of getting the right diagnosis and treatment because it may result in incorrect detection of blood groups, or may cause intravascular hemolysis during surgery or, if blool is given not pre-heated.

Material and Methods: In this study, a patient who faced difficulty during blood drawing and had an apparent blood clot in the hemogram tube. Samples were drawn into K3-EDTA, Na-citrate and K3-EDTA tubes bathed at 37ºC.

Results: Complete blood count was performed and the results were a follows; In K3-EDTA tube erythrocytes were 0.35 106/mm3, MCH and MCHC were +++++, hemoglobin level was 11.5 g/dl, and platelets were 212 103/mm3. In K3-EDTA tubes bathed at 37ºC, erythrocytes were 1.3 106/mm3, MCH and MCHC were 39.7 pg ve 32.5 g/dl respectively, hemoglobin level was 11.9 g/dl, platelets were 249 103/mm3. The patient's serum showed a monoclonal Ig M Kappa band in the immunofixation electrophoresis.

Conclusions: Cold agglutinin disease should be considered in patients with abnormal blood counts with visible agglutination in the tubes. Misdiagnosis of patients should be prevented.

Citation

Kulaksızoğlu, Sibel, Hamit Yaşar Ellidağ, Esin Eren, and Necat Yılmaz. 2015. “Complete Blood Count in Cold Agglutinin Disease”. Journal of Turkish Clinical Biochemistry 13 (2):069-073. https://turkclinbiochem.org/index.php/pub/article/view/222.

Publish with JTCB

Diamond Open Access

Fully Diamond OA with no APCs and no submission fees. Your research is freely available to readers worldwide from the day it publishes.

30-Day First Decision

Double-blind peer review from an active editorial team returns a first decision in about 30 days, keeping your manuscript moving.

Global Platform

Backed by the Turkish Society of Clinical Biochemistry, JTCB welcomes submissions from researchers worldwide and reaches an international laboratory audience.

Focused Laboratory Scope

Method validation, analyzer comparisons, reference intervals, quality indicators, preanalytical studies, and instructive clinical case reports.

Credible and Discoverable

All manuscripts publish in English and follow ICMJE and COPE guidelines, with Crossref DOIs and TR Dizin indexing ensuring global discoverability.